Himalaya Nutradetics own-brand revenue reached 51% in FY26

Himalaya Nutradetics India Limited reported Rs 22.0254 crore of own-brand revenue in FY26, equal to 51.14% of total revenue of Rs 43.0675 crore. The reported own-brand figure was more than ten times the Rs 2.1249 crore disclosed for FY25, shifting the business from a contract-manufacturing-led mix to a near-even split.

How did Himalaya Nutradetics own-brand revenue reach 51% in FY26?

Himalaya Nutradetics own-brand revenue reached 51.14% because reported own-brand revenue rose to Rs 22.0254 crore in FY26 while third-party manufacturing contributed Rs 21.0421 crore. The company sells three own-brand categories: classical Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical supplements. Classical products follow recognised Ayurvedic texts, proprietary products use permitted Ayurvedic ingredients under the AYUSH framework, and nutraceutical supplements are regulated by the Food Safety and Standards Authority of India, or FSSAI.

The change was substantial in absolute as well as mix terms. Own-brand revenue increased from the reported Rs 2.1249 crore in FY25 to Rs 22.0254 crore in FY26, a rise of about 10.4 times based on the disclosed category amounts. In contrast, third-party manufacturing increased from Rs 16.8716 crore to Rs 21.0421 crore over the same period, making its growth smaller than the reported expansion in branded products.

The FY26 mix means own-brand sales exceeded contract-manufacturing revenue by Rs 0.9833 crore. In FY24, however, own-brand products accounted for 28.04% of total revenue of Rs 14.4256 crore, while third-party manufacturing represented 71.96%. The reported FY25 share was 19.65%, indicating that the disclosed move to a 51.14% own-brand contribution occurred within FY26 rather than through a steady three-year progression.

What does the reported revenue data show, and what does it not reconcile?

The revenue data shows a major FY26 change in reported business mix, but the FY25 segment disclosure contains internal inconsistencies. The own-brand amount of Rs 2.1249 crore and third-party amount of Rs 16.8716 crore add to Rs 18.9965 crore, whereas the segment table prints FY25 total revenue of Rs 20.0965 crore. The same table assigns own-brand revenue a 19.65% share, a percentage that does not reconcile to the printed amount and total.

A separate financial-performance disclosure reports FY25 revenue from operations of Rs 20.9965 crore, rather than the Rs 20.0965 crore shown in the segment table. FY26 figures are consistent across the supplied disclosures: revenue from operations was Rs 43.0675 crore, earnings before interest, taxes, depreciation and amortisation, or EBITDA, were Rs 8.1034 crore, and profit after tax was Rs 7.3897 crore. The own-brand FY26 figure of Rs 22.0254 crore also reconciles to the stated 51.14% of Rs 43.0675 crore.

The FY26 operating results improved alongside the reported revenue expansion, but the filing does not allocate EBITDA or profit by own-brand and contract-manufacturing segments. EBITDA margin, defined as EBITDA divided by revenue from operations, rose to 18.82% in FY26 from 14.24% in FY25, while net profit margin rose to 17.16% from 10.63%. Those company-wide measures cannot establish that the branded mix alone produced the margin change.

How does the hybrid model support the new sales mix?

Himalaya Nutradetics uses a hybrid model in which own-brand products provide product ownership and positioning while contract manufacturing uses production capacity and generates manufacturing revenue. Its single integrated Hyderabad facility makes softgel capsules, hardgel capsules, tablets, liquid oral products and medicated oils. The facility operates with registrations and licences issued by AYUSH and FSSAI and holds certifications including World Health Organization Good Manufacturing Practices, ISO 9001:2015 and ISO 22000:2018.

Own-brand demand is generated primarily through a doctor-led offline model rather than mass-media advertising. As of March 31, 2026, the company had about 56 sales and marketing personnel, including regional managers and medical representatives; by July 31, 2026, it reported about 58 personnel. The field force conducts scientific detailing, continuing medical education programmes and medical camps, while stockists and super-stockists supply pharmacies and clinics after primary sales by the company.

Contract manufacturing remains material even after own-brand revenue reached 51.14%. Himalaya Nutradetics provides formulation, manufacturing, packaging and dispatch services to other Ayurvedic and nutraceutical companies against purchase orders, with customers generally responsible for their branding, marketing, distribution and product claims. This division therefore continues to depend on customer orders and available factory capacity, while own-brand growth depends on practitioner engagement, stockist availability and regulatory-compliant product positioning.

Which dependencies could affect the 51% own-brand revenue mix?

The 51% own-brand revenue mix depends on continued branded demand and on maintaining distribution execution across multiple states. Himalaya Nutradetics identifies Telangana, Andhra Pradesh, Kerala, Gujarat and Uttar Pradesh as relatively stronger branded markets, but it does not disclose own-brand revenue by state. Overall revenue remained geographically concentrated: Kerala supplied Rs 21.2472 crore, or 49.33%, of FY26 revenue, while Gujarat and Uttar Pradesh supplied Rs 5.6875 crore and Rs 5.0318 crore respectively.

Third-party manufacturing is more concentrated than the overall revenue data suggests. Approximately 90% of that segment’s revenue comes from Kerala, according to Himalaya Nutradetics, making customer relationships in that state relevant even as contract manufacturing fell to 48.86% of FY26 revenue. A decline in Kerala client orders could reduce capacity utilisation unless replaced by own-brand output or customers from other regions.

Himalaya Nutradetics also identifies raw-material and regulatory risks that affect both segments. Botanical extracts and imported nutraceutical active ingredients can face price and availability volatility, while Ayurvedic and nutraceutical products must comply with evolving AYUSH, FSSAI and advertising rules. Product claims, labelling requirements and approval processes can affect launches and marketing; nutraceutical products have an 18-month shelf life, compared with 36 months for Ayurvedic products.

Conclusion

Himalaya Nutradetics reported a decisive FY26 shift toward own-brand revenue, with Rs 22.0254 crore representing 51.14% of Rs 43.0675 crore total revenue. Contract manufacturing still generated Rs 21.0421 crore and remains important to the single-facility model, so the company has not ceased to rely on third-party work. The FY25 category amounts and percentage disclosures do not fully reconcile, which limits precision in comparing the reported transition with FY25.

The next measure of persistence will be whether own-brand demand remains above half of revenue while Himalaya Nutradetics maintains stockist supply, doctor-led engagement and regulatory compliance. The company says it is evaluating new stock-keeping units, or SKUs, in fertility, bone and joint care, nephrology, metabolic health and paediatrics, subject to internal approvals and regulatory clearances. Management also says it is evaluating a broader geographic spread of contract-manufacturing customers to reduce Kerala concentration.